Clinical Trials Browser

OTHER × Recurrence × durvalumab × Clear all

NCT03999710 2025-11-28

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

61 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Recurrence

NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

Phase 2 Terminated

41 enrolled 13 charts

GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

NCT03723967 2024-04-22

FRAIL-IMMUNE

Phase 2 Completed

104 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Recurrence

NCT03015129 2024-02-06

A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer

Phase 2 Completed

80 enrolled 9 charts

Gynecologic

Recurrence, Endometrial Neoplasms

NCT04015739 2022-08-17

BOLD

Phase 2 Unknown

74 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Recurrence

NCT03799744 2022-03-28

Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma

Phase 1 Unknown

20 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence